To address these challenges, we engineered a next-generation CAR T cell therapy (A20 CAR5 T cells) that not only targets integrin αvβ6 but also secretes an anti-PD-L1 single-chain variable fragment (scFv) within the tumor microenvironment. The gene discussed is CD274; the disease is neoplasm.